On the Cover

Over the past year, Fox Chase Cancer Center has prevailed together. The photos on the cover and inside feature some of our faculty, staff, patients, caregivers and volunteers who have played a key role in this great accomplishment. This list is continued on the inside back cover.

Fox Chase People

Continued From the Inside Cover
Leadership Letter

THIS PAST YEAR, PERHAPS MORE THAN ANY OTHER TIME WE CAN REMEMBER, WE HAVE PREVAILED TOGETHER. ROBERT UZZO, MD, MBA, INTERIM CEO (R), AND JONATHAN CHERNOFF, MD, PHD, CANCER CENTER DIRECTOR (L)

PREVAILING TOGETHER

When we come together, we often can achieve much more than if we had set out alone. Our strength is found in joining with each other, united in a common cause. For us at Fox Chase, it is prevailing over cancer.

This past year, perhaps more than any other time we can remember, we have prevailed together. This idea is solidified in our fervent pursuit of cancer discovery and cancer delivery.

Through our renewed integration with the Temple University Health System, we are pursuing growth in new and exciting ways. With significant capital funding and access to a broader range of resources, we are building on and expanding research collaborations; investing in new technologies, equipment, and upgrades; and accelerating progress to offer the most advanced cancer treatments to our patients.

We have welcomed new senior leaders who are infusing new energy into our institution, and we are seeing longtime faculty members step up to guide us further along in our journey. Basic scientists are working with physicians to translate laboratory discoveries into clinical studies of immunotherapies and other treatments. Our surgeons are using new technology to pinpoint and remove breast cancer more precisely, and nurses are providing support beyond their typical duties to help patients cope with cancer amid the challenges of a global pandemic.

Our scientists are studying potential biomarkers, including one that could help starve pancreatic cancer cells and awaken the immune system to attack them. Researchers at Fox Chase and peer institutions are collaborating to develop new therapies for patients with hard-to-treat head and neck cancers. And donors are shepherding the innovative ideas of our faculty to help them gather data needed to garner even greater funding from larger sources for their research.

So much of what we learn and accomplish in cancer science and medicine comes from working together. We each draw inspiration from different places, but mutual respect and compassion for one another connect us. When we face obstacles and suffer setbacks, it is often more tolerable when shouldered together. And when we achieve success and celebrate our triumphs, it is that much sweeter when it is shared.

We need each other. And together, we offer our talents and dedication so that we may prevail.

Robert Uzzo, MD, MBA, FACS
Interim CEO of the Hospital at Fox Chase Cancer Center

Jonathan Chernoff, MD, PhD
Cancer Center Director
Institutional
INVESTMENTS UNDERSCORE CONTINUING INTEGRATION OF FOX CHASE AND TEMPLE

When Fox Chase Cancer Center became part of the Temple University Health System (TUHS) in 2012, leaders at both centers touted the potential that the integration of two storied organizations offered for quality patient care, as well as for supporting excellence and innovation in education and research.

That integration is as strong as ever, as evidenced by the $20 million that TUHS spent in fiscal year 2021 to provide new state-of-the-art surgical, imaging, and basic research tools at Fox Chase.

It also signifies a major step forward, aligning with the vision set forth publicly by Michael Young, MHA, FACHE, the president and CEO of Temple Health, to spend $100 million over five years at Fox Chase. Upcoming capital investment will focus on upgrading ICU facilities and creating private patient rooms at Fox Chase—projects that will further enhance the inpatient experience.

“As we continue to strengthen the integration between Fox Chase and Temple Health, we move toward greater competitive advantage in the Philadelphia region,” said Robert Uzzo, MD, MBA, FACS, Interim CEO of the Hospital at Fox Chase Cancer Center. “Temple’s success in positioning itself for a stronger future affords greater investment in Fox Chase, and we are seeing this progress taking place.”

Integration also extends to faculty. In March 2021, Erica Golemis, PhD, Deputy Chief Science Officer at Fox Chase, was named chair of the newly created Department of Cancer & Cellular Biology at the Lewis Katz School of Medicine (LKSOM) at Temple University.

“Dr. Golemis’ LKSOM appointment is significant as we move toward greater integration with Temple Health,” said Jonathan Chernoff, MD, PhD, Cancer Center Director. “The formation of the Department of Cancer & Cellular Biology will help us to bring together researchers with associated interests and expertise from across the health system, capitalize on our strengths, create synergy of efforts, increase funding, promote diversity, and ultimately, raise the national profile of this program and our institutions.”

In addition to Golemis, another dual appointment is Tomasz Skorski, MD, PhD, DSc, who is a director of the Fels Cancer Institute for Personalized Medicine at LKSOM, and an associate director and associate professor in the Blood Cell Development and Function Program at Fox Chase. Glenn Rall, PhD, Chief Academic Officer at Fox Chase, is also Assistant Dean of Faculty Affairs at LKSOM.

Fox Chase will also be expanding its high-risk breast cancer and prostate cancer clinics, with appointments one day per month for each service at Temple University Hospital. There are also plans for Fox Chase staff to provide genetic counseling services at Temple University Hospital. “These integration efforts with Temple will further position Fox Chase as leader of all oncology-related services throughout the health system and draw upon Temple’s patient base to further grow our clinical enterprise,” Uzzo said.

IN MEMORY OF JOHN M. DALY, MD, FACS

It was with great sadness that Temple University Health System announced the passing of former Fox Chase Cancer Center faculty member John M. Daly, MD, FACS, on March 26, 2021. Daly was an internationally known surgeon and educator whose clinical work and research spanned the fields of surgical
ERICA GOLEMIS, PHD, WAS NAMED CHAIR OF THE NEWLY CREATED DEPARTMENT OF CANCER & CELLULAR BIOLOGY AT THE LEWIS KATZ SCHOOL OF MEDICINE AT TEMPLE UNIVERSITY.
Institutional

A native of Philadelphia, Daly received his medical degree from Temple in 1973; from 2002 through 2011, he served as dean of his medical alma mater. In 2011, he returned to the practice of surgical oncology as the Harry C. Donahoo Professor of Surgery at Fox Chase Cancer Center, where he specialized in the care of patients with cancers of the gastrointestinal tract and breast.

A true servant-leader, he led multiple medical associations and mentored numerous research trainees, and also received numerous teaching awards and two honorary fellowships for his dedication to students and residents.

In 2019, he returned as dean of the Lewis Katz School of Medicine at Temple, where he led it through a restructuring, worked hand-in-hand with students to address racial and social justice issues in medical education, and navigated the school through a once-in-a-generation pandemic.

Daly will be remembered as a skilled teacher, mentor, and surgeon, a loving father and grandfather, a devoted husband, and an exceptional, tireless, and remarkably kind human being. He was predeceased by his first wife, Mary F. Daly, and is survived by their six children, his wife, Palma, and many grandchildren.

Mary F. Daly, and is survived by their six children, his wife, Palma, and many grandchildren.

ROLLOUT OF COVID-19 VACCINE

The dark shadow of COVID-19 loomed over the world in 2020 and 2021, and healthcare facilities were no exception. But that darkness began to dissipate in December of 2020 when Fox Chase began vaccinating frontline staff at the Main Campus and then steadily expanded efforts to reach an increasing number of people, with patient clinics opening in early February and clinics being set up at the Buckingham and East Norriton locations.

Between December 2020 and June 2021, more than 7,000 Fox Chase patients were vaccinated against COVID-19.

“Rollout of COVID-19 vaccine”

When the effort wound down in June 2021, more than 14,000 shots had been administered to more than 7,000 patients, and many Fox Chase employees had been vaccinated against COVID-19, with an even higher percentage of vaccinations in many clinical areas.

“This is a tremendous achievement,” said Robert Uzzo, MD, MBA, FACS, Interim CEO of the Hospital at Fox Chase Cancer Center. “It is because of an incredible team of professionals and volunteers—both clinical and non-clinical—that Fox Chase carried out the...
Patients were very scared and had a lot of questions. They wanted to know if they could still have treatment for their cancer. My nursing staff was in overdrive and very overwhelmed. Our calls went from about 400 calls a day to about 800 to a thousand calls a day,” she said.

Unfortunately for nurses, working from home wasn’t an option. “From the beginning, we were here every day and maintaining our volumes,” said Tara DelGrippo, MSN, RN, NE-BC, OCN, clinical director of Ambulatory Care and Infusion Services.

planning, staffing, and daily operations of such an immense project to provide needed vaccinations to both our patients and our employees.”

NURSES ON THE FRONT LINES OF COVID-19

In March 2020, Fox Chase Cancer Center was among thousands of healthcare facilities around the country facing the challenge of providing a continued high standard of care while adapting to changing information and protocols surrounding the emergence of COVID-19 in the United States.

At the forefront of this pandemic were nurses who, day in and day out, are charged with not only caring for the physical health and mental well-being of their patients, but also with an immeasurable amount of behind-the-scenes work that ensures that operations run smoothly.

One of the most significant challenges for nurses was the emotional toll of the virus. Rebecca Farrell, MSN, RN, clinical manager at Fox Chase Cancer Center - Huntingdon Pike, said their phone triage was flooded with concerned patients in the first few weeks of the pandemic.

“Patients were very scared and had a lot of questions. They wanted to know if they could still have treatment for their cancer. My nursing staff was in overdrive and very overwhelmed. Our calls went from about 400 calls a day to about 800 to a thousand calls a day,” she said.
NURSES CONTINUE TO GIVE
Despite the many challenges that the COVID-19 pandemic has presented, nurses at Fox Chase Cancer Center consistently found ways to encourage and care for patients who are still navigating their cancer journey. One example of this is the We Care Project, created by ambulatory care nurse Kelly Bailey, RN, BSN.

Bailey had a young patient with colon cancer and she found out it was his birthday, but he was by himself because patients weren’t allowed to have visitors due to the pandemic.

“She ran all over the building to find a birthday gift for him,” said Christine Kappler, a clinic assistant at Fox Chase who helped Bailey develop the project.

“She came up with the idea that we needed to do something for these
GLENN RALL, PHD, WAS NAMED ASSISTANT DEAN OF FACULTY AFFAIRS AT THE LEWIS KATZ SCHOOL OF MEDICINE AT TEMPLE UNIVERSITY.
patients during COVID because they’re anxious, they’re sad, and we should just let them know they’re loved and we’re here for them,” Kappler added.

Bailey took the idea to management, who then implemented the program. Nurses in the department helped donate gifts, and as news spread throughout Fox Chase, Kappler said they have been receiving donations from co-workers, doctors, and outside donors.

Kappler recalled one instance where a patient was brought to tears by a gift. “His wife had just died about a month ago and this was probably the only present he would be getting for his birthday. So it has just been really touching.”

**JOEL HELMKE JOINS CENTER AS NEW CHIEF OPERATING OFFICER**

Joel Helmke, MSHP, FACHE, has joined the Fox Chase Cancer Center senior leadership team as chief operating officer, where he will be in charge of directing clinical and business operations.

“By bringing industry best practices and new perspectives, he will help us refine our processes and enhance our facilities to match the talent and expertise we already have in our faculty and staff,” said Robert Uzzo, MD, MBA, FACS, Interim CEO of the Hospital at Fox Chase Cancer Center.

Uzzo said Helmke will continue to propel integration efforts between Fox Chase and Temple University Health System, which Fox Chase is a part of. Before joining Fox Chase, Helmke served nearly five years as senior vice president of clinical operations at City of Hope National Medical Center in Duarte, Calif., a National Cancer Institute-designated comprehensive cancer center and 32-site cancer network.

**ANNA LIZA RODRIGUEZ NAMED NEW CHIEF NURSING OFFICER**

Anna Liza Rodriguez, MSN, MHA, RN, OCN, NEA-BC, has become chief nursing officer and vice president of nursing and patient services at Fox Chase.

“By bringing industry best practices and new perspectives, he will help us refine our processes and enhance our facilities to match the talent and expertise we already have in our faculty and staff,” said Robert Uzzo, MD, MBA, FACS, Interim CEO of the Hospital at Fox Chase Cancer Center.

Uzzo said Helmke will continue to propel integration efforts between Fox Chase and Temple University Health System, which Fox Chase is a part of. Before joining Fox Chase, Helmke served nearly five years as senior vice president of clinical operations at City of Hope National Medical Center in Duarte, Calif., a National Cancer Institute-designated comprehensive cancer center and 32-site cancer network.

**FOX CHASE REGISTERED**

**140,503**

**OUTPATIENT VISITS AND**

**8,631**

**NEW PATIENTS.**
to the individual needs of every patient, supporting our nursing professionals and leaders, and further advancing the quality of care both at Fox Chase and throughout Temple University Health System,” said Robert Uzzo, MD, MBA, FACS, Interim CEO of the Hospital at Fox Chase Cancer Center.

Before coming to Fox Chase, Rodriguez served for nearly five years as associate nursing officer at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. Vanderbilt is a top National Cancer Institute-designated comprehensive cancer center.

FOX CHASE RECEIVES GUARDIAN OF EXCELLENCE AWARD

Press Ganey has recognized Fox Chase Cancer Center with its 2020 Guardian of Excellence Award for providing outstanding clinical performance for patients in its outpatient clinics.

Press Ganey is an independent market leader in helping healthcare institutions measure patient satisfaction and better understand the patient experience. “This kind of recognition is meaningful because it originates from feedback provided by our own patients,” said Robert Uzzo, MD, MBA, FACS, Interim CEO of the Hospital at Fox Chase Cancer Center.

Performance data comes from the Clinician and Group Consumer Assessment of Healthcare Providers and Systems survey, which is administered by the U.S. Department of Health and Human Services through its Agency for Healthcare Research and Quality.
BONE MARROW TRANSPLANT DEPARTMENT RECOGNIZED FOR EXCEPTIONAL SURVIVAL OUTCOMES

The Fox Chase-Temple University Hospital Department of Bone Marrow Transplant and Cellular Therapies was recently recognized for exceptional performance in successful transplant procedures, making it the second year in a row that the center has achieved this distinction.

Each year, the Center for International Blood & Marrow Transplant Research (CIBMTR) performs a center-specific survival analysis providing one-year survival rates among 170 centers in the United States. The report contains outcomes for transplants using both related and unrelated donors.

The CIBMTR identified Fox Chase as having some of the best survival outcomes, a distinction it shares with only 16 other centers across the nation. Fox Chase is the only center in the tristate area listed for two years in a row.

Henry Chi Hang Fung, MD, FACP, FRCPE, chair of the department, said the honor is due to several essential factors, including strong program leadership, an expert multidisciplinary team, and close collaboration with community physicians.

NURSES HONORED WITH PRESTIGIOUS ‘I AM PATIENT SAFETY’ ACHIEVEMENT AWARD

A nursing team was honored as a recipient of the 2021 I AM Patient Safety award from the Patient Safety Authority. The team was awarded the Executive Director’s Choice award, making it one of 11 healthcare facilities in Pennsylvania to be recognized for their advancements, outcomes, and commitment to patient safety.

The third floor surgical nursing team was recognized for reaching the significant milestone of one year with no patient falls on their three south unit. This milestone supports the nursing department’s Zero Harm program, a patient safety initiative that focuses on limiting preventable harm in the healthcare environment.

“We are so proud of this Magnet team and their leaders for their commitment to target zero patient harm. That quest and dedication led to the achievement of no patient falls for one year and well-deserved statewide recognition,” said Kathleen Wolf, Magnet Program/Nursing Quality Director.

A DEDICATED GROUP OF 277 VOLUNTEERS DONATED 67,034 HOURS OF SERVICE.
TOMASZ SKORSKI, MD, PHD, DSC, HAS DUAL APPOINTMENTS AT TEMPLE AND FOX CHASE, WHERE HE IS AN ASSOCIATE DIRECTOR.
Clinical

CLINICAL TRIALS PAVE THE WAY FOR LIFE-CHANGING TREATMENT

Clinical trials are the method that doctors use to develop and bring new drugs to patients. Phase 1 cancer therapy trials are the first step in that process. Clinical trials are one of the most important stepping-stones on the path to finding new treatment methods and options for patients with cancer.

“Sometimes these trials are your last hope,” said Stephanie Heart, a malignant melanoma patient who was treated at Fox Chase with a cutting-edge drug that was tested in a clinical trial. Although she did not participate in that trial, she ultimately benefitted from it.

Fox Chase Cancer Center is one of few institutions in the Philadelphia area that conducts these essential trials for patients with cancer. Fox Chase conducts hundreds of clinical trials a year, including studies that involve giving patients treatment for their disease and non-interventional studies that are lab-based or observational. Many of these trials, particularly those that make it to the later stages, have helped patients live longer and have a higher quality of life.

Fox Chase is very active in clinical trials, with 121 intervention/treatment studies presently accepting patients in phases 1, 2, and 3. There are also over 100 non-interventional studies currently ongoing.

“This institution has pioneered a number of major drugs going back decades, including drugs like Taxol,” which was approved for use in 1993, said Martin Edelman, MD, chair of the Department of Hematology/Oncology at Fox Chase and Deputy Cancer Center Director for Clinical Research.

“More recently, we were involved in many of the targeted agents, and most recently, immunotherapeutics. As one of my colleagues put it, ‘In general, patients at Fox Chase have the potential to get one of these drugs years before it becomes available to the general public.’”

Anthony Olszanski, MD, RPh, a medical oncologist at Fox Chase and director of the Early Clinical Drug Development Phase 1 Program, said that despite their benefit, there is a lot of misinformation about clinical trials.

“Sometimes patients’ family members will talk patients out of participating in them, not fully understanding why the research was offered. They often misunderstand the amount of care they will get in a clinical trial. Most guidelines like the National Comprehensive Cancer Network guidelines actually state that the best way to receive cancer care is through a clinical trial.”

In addition, Olszanski said, it is important for patients and their families to recognize that all clinical trials are completely voluntary. “That means a patient can sign up for a clinical trial but decide not to participate in the clinical trial at any point. They can stop doing it at any point in time if they get uncomfortable about it, if they have side effects because of the drug, or if some other life-changing event happens. Participation is always in the patient’s control.”

HOLISTIC APPROACHES TO GERIATRIC ONCOLOGY

There is nothing standard about caring for the oldest cancer population in the United States. Cancer care can be complicated, and treatment can become even more complex as patients age. Geriatric oncology is an area of medicine that considers the best ways to treat such patients.

ACTIVELY ENROLLING CLINICAL RESEARCH STUDIES: 294.
ANTHONY OLSZANSKI, MD, RPH, IS A MEDICAL ONCOLOGIST AND DIRECTOR OF THE EARLY CLINICAL DRUG DEVELOPMENT PHASE 1 PROGRAM.
Experts in the field say physicians need to look at older patients more holistically by considering not just how to treat their cancer, but also other factors such as comorbidities like diabetes and heart disease, as well as their cognitive function and social environment. Researchers say they also hope to advance the field by obtaining more clinical data specific to the care of older adults with cancer.

Perhaps no one is more familiar with these needs than Efrat Dotan, MD, a medical oncologist at Fox Chase specializing in gastrointestinal cancers. Dotan has been working in geriatric oncology since 2010 and has been at the forefront of researching and developing new ways of thinking about the field.

"Medical oncology is an art. There’s no one treatment that fits all," said Dotan. "The way to think about this is that we have to look at the patient in front of us and understand their overall goals and ability to tolerate therapy as we develop a personalized treatment plan."

OFFERING CUTTING-EDGE CELLULAR THERAPIES
Fox Chase’s Department of Bone Marrow Transplant and Cellular Therapies, which is chaired by Henry Chi Hang Fung, MD, FACP, FRCPE, is now certified to offer five cellular therapy options for patients with blood cancers, changing the outlook for these patients. In these therapies, a patient’s T cells are collected and modified to fight cancer before being infused back into the patient’s body.

The five cellular therapy options include:
• ABECMA: Approved to treat patients with relapsed or refractory multiple myeloma.
• BREYANZI: Approved to treat patients with relapsed or refractory large B cell lymphoma.

• KYMRIAH: Approved to treat patients with relapsed or refractory large B cell lymphoma and patients ages 18 to 25 with relapsed or refractory B-cell acute lymphoblastic leukemia.

• TECARTUS: Approved to treat patients with relapsed or refractory mantle cell lymphoma.

• YESCARTA: Approved in 2017 to treat patients with relapsed or refractory large B cell lymphoma and in 2021 for patients with relapsed or refractory lymphoma.

NEW SURGICAL NAVIGATION TECHNOLOGY FOR BREAST-CONSERVING SURGERIES

Fox Chase Cancer Center has become the first cancer center in the Northeast to feature a new tumor marker technology that has been described as the next generation of surgical navigation, one that will make breast excisional biopsies and breast-conserving surgeries more precise.

Breast surgeons have had few tools available to guide them in the removal of cancerous breast tissue, but with the EnVisio real-time Surgical Navigation System and SmartClip Tumor Marker technology, surgeons will be better able to navigate to the precise location of malignant breast tissue during a lumpectomy, significantly advancing breast care.

“The EnVisio navigation system is a step up from other technologies on the market for localization of tumors because it shows the tumor relative to the detector in three dimensions on a screen, making it easier for the surgeon to assess where the tumor is and how best to resect it,” said Richard J. Bleicher, MD, FACS, a professor in the Department of Surgical Oncology.

THE MOST COMMON TYPES OF CANCER AMONG PATIENTS TREATED AT FOX CHASE:

PROSTATE
(21%),

BREAST
(17%),

LUNG
(10%),

AND GYNECOLOGICAL
(8%).
“THIS INSTITUTION HAS PIONEERED A NUMBER OF MAJOR DRUGS GOING BACK DECADES, INCLUDING DRUGS LIKE TAXOL.”
MARTIN EDELMAN, MD, CHAIR OF HEMATOLOGY/ONCOLOGY
Research
Several researchers at Fox Chase Cancer Center have received grants through the National Institute of Dental and Craniofacial Research-funded Specialized Program of Research Excellence (SPORE) for Head and Neck Cancer.

Head and neck cancers are a group of malignancies that start in the lining of the mouth, throat, voice box, or nose. Mostly squamous cell carcinomas, they account for approximately 4% of all cancers in the United States and can require complex treatment, according to the National Cancer Institute.

A five-year, $11.7 million grant will fund a SPORE collaboration among researchers at Fox Chase Cancer Center, Yale Cancer Center, and the University of North Carolina Lineberger Cancer Center to address obstacles in treating head and neck squamous cell carcinoma.

“It’s an exciting opportunity to focus sustained effort on improving treatment for this devastating disease,” said Erica Golemis, PhD, Deputy Chief Science Officer and co-leader of the Molecular Therapeutics Program. Golemis co-leads one of the central projects supported by the SPORE with a collaborator at Yale, Barbara Burtness, MD, and is site director for Fox Chase.

“This collaborative project aims to develop a new therapy for patients that have resistance to normal forms of treatment for advanced head and neck cancer. As a SPORE project, it’s designed fundamentally to connect insights in the labs directly to clinical trials taking place at Yale, Fox Chase, and Lineberger,” Golemis added.

“SPORE grants are among the most prestigious awards bestowed by the National Institutes of Health and fund critical translational research by teams of basic scientists and clinical researchers,” said Jonathan Chernoff, MD, PhD, Cancer Center Director. “Under the exceptional leadership of Dr. Golemis, we at Fox Chase are honored to collaborate with the other centers to bring about important treatment advances for patients with head and neck cancers.”

The United States Congress established SPOREs to promote interdisciplinary research and help basic research findings move quickly from the laboratory to the patient. The grants are highly competitive. In order to earn one, institutions must demonstrate a high degree of collaboration between first-rate scientists and clinicians, and show excellence in translational research projects.

John A. “Drew” Ridge, MD, PhD, FACS, chief of the Division of Head and Neck Surgery, will play a key role in advising the research funded by the grant. Ridge has been at Fox Chase since 1991, when he came to join one of the country’s first multispecialty head and neck cancer teams, and is a nationally recognized figure in the field.

Camille Ragin, PhD, MPH, a professor in the Cancer Prevention and Control Program, received competitive funding from the Developmental Research Program within the SPORE. The funding supports promising early stage projects that may develop into full projects. Ragin’s study will focus on differences in cancer risk and disease course between Black and white populations, which is aligned with one of Ragin’s research interests, disparities in cancer care for underserved patient populations.

Sanjeevani Arora, PhD, assistant professor in the Cancer Prevention and Control Program, also received a related grant from the SPORE’s Career Enhancement Program Award program. Arora will receive a one-year grant of $50,000 and eligibility for a second year of funding to support development of
DISPARITIES IN CANCER CARE FOR UNDERSERVED POPULATIONS IS ONE AREA OF RESEARCH FOR CAMILLE RAGIN, PHD, MPH, OF THE CANCER PREVENTION AND CONTROL PROGRAM.
new research directions that enhance head and neck cancer prognosis. Golemis will be Arora’s primary mentor on this research.

Other Fox Chase faculty participating in the SPORE research include Eric Ross, PhD, ScM; Denise Connolly, PhD; and Douglas Flieder, MD.

NEW CANCER EPIGENETICS INSTITUTE LAUNCHED
Fox Chase Cancer Center has launched a new Cancer Epigenetics Institute (CEI) that will create a locally based national hub for epigenetics study and collaboration focused on mechanisms promoting cancer and therapeutic resistance.

Epigenetics is the study of how modifications to DNA and the environment surrounding DNA impact the way genes are expressed and the stability of DNA without changing its sequence. In cancer research, epigenetics is used to understand how cancer cells react to their environments and discover ways to control those reactions.

The mission for the new CEI is to facilitate academic-to-industry and academic-to-academic partnerships with the goal of promoting discovery in cancer epigenetics. The aim of those discovery efforts is to reduce the morbidity and mortality associated with cancer by focusing on biomarker research and therapeutic interventions.

“The benefit of the new institute is that it increases the focus on epigenetic mechanisms driving cancer and helps facilitate center-wide collaborations,” said Johnathan R. Whetstine, PhD, founding director of the institute, who is also a professor and co-program leader for the Cancer Signaling and Epigenetics Program.

RESEARCHER RECEIVES 2020 NIH DIRECTOR’S NEW INNOVATOR AWARD
Joan Font-Burgada, PhD, an assistant professor in the Cancer Signaling and Epigenetics Program, has received a National Institutes of Health (NIH) Director’s New Innovator Award from the NIH Common Fund.

“I am really grateful to the NIH for promoting the High-Risk, High-Reward Research program and supporting early stage investigators like myself. This initiative encourages us to be imaginative and bold in tackling unsolved biomedical issues,” said Font-Burgada.

RESEARCHERS HAD 526 SCIENTIFIC ARTICLES PUBLISHED.
His research focuses on cancer metastasis, which is the direct cause of over 90% of cancer deaths. Historically, research has focused on determining specific properties of the metastatic cells that could be used to develop therapies. This approach has become unattainable because of the high genetic diversity of metastatic cells, resulting in multiple “unique” tumors in a single patient.

Font-Burgada proposes switching the spotlight from metastatic cells to the so-called metastasis-interacting resident cells. If successful, this approach could result in effective treatments for many patients regardless of cancer type, with the additional benefit of reduced resistance, since the cells being targeted are not cancer cells and therefore devoid of escape strategies.

ROLE OF LIPIDS IN CONTROLLING PANCREATIC CANCER AGGRESSIVENESS
Altering lipid metabolism may contribute to sustaining tumor growth in patients with pancreatic ductal adenocarcinoma, a finding that could help overcome a major problem in pancreatic cancer treatment resistance and metastatic spread.

“The initial assumption was that if we block biosynthesis of cholesterol in cancer cells, that should prevent cancer development,” said Igor Astsaturov, MD, PhD, of the Department of Hematology/Oncology, the lead author of the study, which was a complex, multifaceted investigation involving a number of Fox Chase Cancer Center researchers. The study was published in the prestigious journal Cancer Cell.
But they were not able to prove the hypothesis, he said. “Working collaboratively, we found, quite disturbingly, that patients who take statins and have a lower level of blood cholesterol have a higher prevalence of the EMT cells in their tumors,” Astsaturov said. EMT stands for epithelial-mesenchymal transition, which is the hallmark feature of a subtype of pancreatic cancer known as basal.

He added that researchers are now beginning to look at a larger collection of human samples to determine how blood lipids correlate with a patients’ nutrition, medicines they are taking, and the percentage of EMT cells in their tumors.

‘DORMANCY’ IN AML ALLOWS CANCER CELL SURVIVAL

A study has helped to identify a cellular resilience mechanism through which acute myeloid leukemia (AML) cells survive cancer treatment, causing disease relapse. The research also suggests that certain drugs could be used to destroy these treatment-surviving AML cells.

Cihangir Duy, PhD, assistant professor in the Cancer Signaling and Epigenetics Program at Fox Chase, who led the study, had observed in earlier research that AML cells enter a senescent state in response to chemotherapy that has the potential to re-initiate leukemia. Senescence, another word for cellular aging, is the point at which cells lose their ability to divide and grow.

Past studies suggested that AML relapse was caused by the presence of inherently more resistant leukemia stem cells. Instead, Duy and colleagues found that when patient-derived AML cells were treated with chemotherapy, many cells died, but a fraction survived, regardless of whether they were leukemia stem cells. These residual cells were large, stopped growing, and showed markers of cellular senescence.

Temporarily entering this senescence-like phase allows AML cells to endure chemotherapy; subsequently, these protected AML cells awaken and are able to begin dividing again.

NEW TARGET COULD STARVE CANCER AND ACTIVATE IMMUNE SYSTEM

Researchers identified a new biomarker and potential novel treatment target for pancreatic ductal adenocarcinoma (PDAC) that could help starve cancer cells and allow the immune system to attack tumors.

The target is a brain synaptic protein called Netrin G1 (NetG1), which was found to be ectopically expressed in the fibroblastic cells of the pancreas and also found to have a dual role in supporting PDAC survival. The role of NetG1 was discovered in the lab of Edna Cukierman, PhD, a professor in the Cancer Signaling and Epigenetics Program.

“It is difficult for the pancreatic cancer cells to get nutrition,” Cukierman said. “When we got rid of the NetG1 protein in cancer-associated fibroblasts, the cells looked the same but stopped providing nutritional benefit to the cancer cells.”

The researchers also found that NetG1-positive cancer-associated fibroblasts are intrinsically immunosuppressive and prevent the immune system from attacking cancer cells. The study was published in the prestigious journal Cancer Discovery.

Most importantly, Cukierman and colleagues used an antibody to neutralize NetG1 in an animal model. This antibody helped kill the tumor and showed evidence of reactivation of the immune system to effectively stall tumor progression.

“In pancreatic cancer we have been hungry for something that could help us to rehabilitate the immune system to be able to kill cancer,” Cukierman said. “This paper proposes a new target to awaken the immune system while starving cancer cells at the same time.”

A TOTAL OF 479 RESEARCH PROJECTS WITH $72 Million IN TOTAL COSTS RECEIVED FUNDING.
Philanthropy
Philanthropy

PHILANTHROPY FUNDS ENDOMETRIAL CANCER RESEARCH

Research at Fox Chase Cancer Center is fundamental in the discovery and implementation of new and effective cancer treatments. Much of this research, however, would not be possible without help from organizations whose goals align with the mission of Fox Chase.

For some organizations, like Peggy’s Pathway for Women’s Cancer Care, the work being done at Fox Chase has sparked inspiration to aid in the development of new therapies that could potentially help patients with few options.

Peggy’s Pathway was started in honor of former Fox Chase patient Peggy Pettinato, a bookkeeper, real estate agent, and avid community volunteer who passed away from serous endometrial carcinoma. Natalie O’Hara, Peggy’s daughter and one of the founders of Peggy’s Pathway, began searching for organizations that fund endometrial cancer research. To her surprise, there were not many to choose from.

As a result, O’Hara’s father, Bob Pettinato, began speaking with Gina M. Mantia-Smaldone, MD, associate professor in the Department of Surgical Oncology, about raising money for endometrial cancer research along with O’Hara, her three siblings, and their spouses.

“Dr. Gina treated my mother’s endometrial cancer. Despite her best efforts, the standard treatment protocol of the time was not able to save my mother’s life,” said O’Hara. “During the course of her treatments, my parents grew close to Dr. Gina and came to rely on her.”

Mantia-Smaldone worked with James S. Duncan, PhD, an associate professor in the Cancer Signaling and Epigenetics Program, to develop a proposal for the initial phase of research that ultimately became the project for Peggy’s Pathway.

Using a technology called multiplexed inhibitor beads and mass spectrometry, Duncan and other researchers profiled the kinome of endometrial tumors and normal endometrial tissues and identified a network of kinases that were overexpressed, including serine/arginine-rich splicing factor kinase 1 (SRPK1). Duncan and colleagues are planning to further explore how SRPK1 works by applying proteomic technology.

“This project really sums up the concept of a lot of the work that Fox Chase is trying to do when it comes to research,” Duncan said. “Peggy’s Pathway selected our project for funding because they thought our approach of looking at kinase signaling looked interesting, and, as a result, we have found something that may be actionable.”

Peggy’s Pathway now has the goal of raising at least $200,000 over the next two years to fund some of this research at Fox Chase. Because of COVID-19, they had to cancel their annual fundraisers in 2020 and 2021, but they are planning to hold one in 2022. The Pettinato’s 12 grandchildren pitch in by helping with fundraisers.

“We see the role of Peggy’s Pathway for Women’s Cancer Care as that of a seed or catalyst to get the research far enough along that it becomes viable for a larger funding source to bring it to fruition,” said Bob Pettinato. “Our goal here is to save women’s lives by creating an innovative treatment to successfully treat the serous endometrial carcinomas that can’t be eliminated by current protocols.”

THE 7TH ANNUAL IN VINO VITA BENEFIT AND WINE AUCTION RAISED MORE THAN $700,000 IN SUPPORT OF CANCER RESEARCH.

FOX CHASE PHILANTHROPY GOING STRONG

Despite the challenge of operating amid the pandemic, the Institutional Advancement team, the philanthropic arm of Fox Chase Cancer Center, had many noteworthy accomplishments. Below are a few highlights from the past fiscal year:
PEGGY’S PATHWAY WAS STARTED IN HONOR OF FORMER FOX CHASE PATIENT PEGGY PETTINATO BY HER HUSBAND, BOB PETTINATO, AND HER DAUGHTER, NATALIE O’HARA.
• Fox Chase again exceeded its annual fundraising goal by raising nearly $17 million, enabling new and expanded programs and services, and more cancer research.

• Although spending time together in person is certainly preferable, Institutional Advancement has become adept at producing high quality virtual and hybrid events. In addition to In Vino Vita, Fox Chase’s signature fundraising event, the team held a month-long virtual version of Paws for the Cause, the annual Tree of Life lighting ceremony, and a President’s Reception for members of the Laurel Society. It also produced several educational programs on a variety of cancers as part of the popular “Together Facing” series.

• Longtime supporters Lauren and Don Morel made a commitment of $1.2 million to fund early-stage cancer research.

• Fox Chase’s Teen Research Internship Program is now eligible for support through the Pennsylvania Educational Improvement Tax Credit (EITC) program. EITC status allows businesses to receive a significant reduction in state tax in exchange for supporting this innovative educational program. For more information, contact giving@fccc.edu.

**IN VINO VITA RAISES MORE THAN $700,000**

Fox Chase Cancer Center presented its signature fundraising event, In Vino Vita, on October 2, 2020. The seventh annual event was held virtually for the first time and raised over $700,000 for cancer research at Fox Chase.

Each year, In Vino Vita, which is usually held in Center City Philadelphia, has featured live music, a multicourse dinner, and an auction of high-end wine and related experiences. This year, guests were invited to participate from home. The online event still included entertainment, as well as live and silent auctions where the highest bidder could win experiences from top winemaking talent.

As in previous years, the event featured the Special Pledge as the highlight of the evening. The purpose of the pledge is to focus fundraising efforts on a significant opportunity that will directly impact the future of cancer research, treatment, and care at Fox Chase.

This year’s pledge focused on funding young investigators in cancer research with the goal of providing resources to young researchers who are poised to make breakthroughs. The funding will enable them to pursue original research, earn advanced degrees, and collaborate with their peers in an environment where competition for funding is extremely fierce and opportunities are limited. Of the $700,000 raised this year during In Vino Vita, $400,000 was for the Special Pledge.

**PAWS FOR THE CAUSE A VIRTUAL EXPERIENCE IN 2020**

Although attendees could not gather at Fox Chase Cancer Center for the 21st annual Paws for the Cause dog walk, the event’s new virtual format offered the opportunity for participants to connect and walk together virtually, creating a spirit of warmth and camaraderie throughout the month-long October celebration.

Thanks to 341 donors and sponsorship support led by title sponsor West Pharmaceutical Services Inc., Paws raised more than $131,000 in support of cancer research.

Hosted by the center’s Board of Associates, the event highlights included a kickoff “Pup Rally” video featuring emcee Sue Serio from Fox 29 and her dog Rufus, remarks from senior leadership, Physician and Patient Ambassadors, and more.
MONEY RAISED BY PEGGY’S PATHWAY FUNDED RESEARCH INTO KINASE SIGNALING BY JAMES S. DUNCAN, PHD, OF THE CANCER SIGNALING AND EPIGENETICS PROGRAM.
The Laurel Society

The Laurel Society is the signature donor society of Fox Chase Cancer Center, honoring our most generous supporters—individuals, corporations, foundations, community fundraisers, and Fox Chase faculty and staff. Individual members demonstrate their commitment by providing annual support of $1,000 or more during Fox Chase’s fiscal year (July 1 through June 30). Corporations, foundations, and community fundraisers become members at the $5,000+ level.

Founders’ Circle

$500,000 +

Anonymous
Concetta Greenberg*
Susan & William G. Little
Lauren & Donald E. Morel Jr.

Chairmen’s Circle

$100,000 - $499,999

Anonymous
Gay & John K. Binswanger
Carol A. & Louis E. Della Penna Sr.
The Estate of Helen Hendrickson
David P. Ineich
The Estate of Alma R. Jacobs
Janet B. Kovacs
Jeanne Leinen
The Estate of Denise Petti
Robert W. Pettinato
Clare K. Perac
John Ruggio
Claire & William R. Sauter
Daphne Sawyer
Roberta R. & Ernest Scheller Jr.

Advocates’ Circle

$25,000 - $99,999

Anonymous
Maggie & Bob Beck
Betty Ann & R. Reginald Bishop
David B. Campbell
The Estate of Ruth G. Collins
Carolyn Dryden
The Estate of Yvonne Eldridge
Janet F. & Paul F. Engstrom
Susan C. & William J. Federici
Susan G. & Richard I. Fisher
Rosalie Formiglia
Donna & Stephen M. Fuga
Renee & Neil F. Hall
The Estate of Edith D. Higley
Kay & Thomas W. Hofmann
Aurora M. & Timothy P. Hughes
The Estate of Greta J. Kling
Alice G. & Peter M. Kreindler
Judith & Thomas K. Leidy
Naomi P. & Philip E. Lippincott
Sandra G. & David G. Marshall
The Estate of
Christina M. McNally
Salli & Stephen R. Mickelberg
The Estate of Morton B. Parmet
Tina M. Pidgeon & Timothy H. Fitzpatrick
Ann L. & Frank E. Reed
The Estate of Jean E. Schlegel
Debra & Leo M. Sniger
Robin L. & John C. Spurillo
Tania & Robert Stutman
Nancy K. Switzer
Margot Wallace Keith & Robert E. Keith

Champions’ Circle

$10,000 - $24,999

The Estate of Alice C. Bassett
Michael Bienenfeld
Cindy & Jack Bienenfeld
Claire G. & Bernard A. Borghel
Lizbeth A. & Ed Brunswick
Christine M. Cardamone & William Dauksys
Reina S. & Michael A. Cohen
Martin Conlon
Frank J. Crowley
Wei-Je Cui & Ting L. Shi
The Estate of
Camille Jeanne Dawson
The Estate of Joan M. & John A. Dietze
Denise M. & Timothy J. Donahue
Elaine T. Emrick
Mary R. & Joseph Faulkner
Bonnie A. & Allen C. Haldeman
Nancy & Kenneth Hellendall
Linda G. & Ivan Inerfeld
Jane M. Laffend
William H. Lambert
Diane S. & Christian F. Martin
Richard B. Milham Jr.
Patricia A. & Bruce A. Ruggeri
Doris B. Salati
Janet B. Schell
Joyce Seewald Sando
Mary Ann Sells & Jonathan Chernoff
Beth E. Solomon & John J. Matthews
Marjorie Stanek
Ruth Weber
The Estate of Ann B. Wilcox
Justin L. Young
Jennifer & Matthew Zelesko

Guardians’ Circle

$5,000 - $9,999

Anne & Grover Albright
Susan J. & Jim Anderson
Anonymous
Ellen G. & Michael Araten
Myra & John M. Ballinger Jr.
Delbert E. Broughton Jr.
Christina S. Chu & Hee Kwon Song
Judy & Douglas E. Cook
The Estate of Emily M. Dannaker
The Estate of Benjamin F. Delong
Ira R. Dolich
Lowell H. Dubrow
Carolyn Y. Fang & John S. Shaw
Frederick Feldman
Karen A. & Michael D. Flynn
Joan E. & Michael J. Foley
Jean A. & G. Wesley Frazier
Sally R. & David L. Frost
Peter Giannamco
Jaclyn & Norman Goldberger
The Estate of Stanley A. Greene
Janice C. Grob
Diane T. & Robert J. Hansberry
Alice M. Hungerford
June & Marc Kantor
Diana Keat & Edward A. Glickman
The Estate of Sheila & Robert H. Kline
Cynthia & Warren Kruger
Richard F. Lamb
Gregory G. Lawton
Armand Lifman
Derek Liu
Denise J. Marshall
The Estate of
Ethel A. McCollaum
Robin & John F. McGeever
Susan Menkovitz
P. Suzanne Miller
The Estate of Lois Ann Oakes
Lillian M. O’Connor
Lisa & Jonathan Otto
Doreen H. Payton*
Beatrice S. Pitcairn
Kathleen G. Pitcairn
Scott Rakestraw
Eileen & Glenn F. Rall
Nancy & Stephen Rauscher
Patricia F. Rissler & James A. Rogers
Krista & Bryan G. Rogers
Jennifer L. & Frank Rupert
Daniele J. Schroetter
Patricia B. & Harris A. Schwartz
Jennifer & Erik F. E. Streitwieser
S. Brad Tanner
Patrons' Circle
$2,500 - $4,999
Carol & Benjamin Baldridge
The Estate of Margaret D. Barber
Dale Boychak
Regina & Robert J. Brennan
David Broda
Eliner & James M. Buck III
Susan Cassel
Jody Cassell
Flo & Richard Celender
Lili Chen & Charlie Ma
Margie L. Clapper &
Donald Carney
Natalie Cuttic
Rose Marie A. Deffenbach &
John McGinley
Margaret & Anthony J. Diasio
Lilian & Michael C. DiPiazza
Sally N. Eisenhauer
Charles P. Fabsko
Frances L. Finkle
Deborah D. Flint
Diane C. & Cameron H. Fowler
Jean & Michael Fowler
Amy L. Freedman &
Michael M. Millenson
Tracy M. Gatto
Lee M. & Harvey Gitlin
Erica A. Golemis & Michael Ochs
Julia Golenerud &
Arland T. Hotchkiss Jr.
Richard E. Greenberg
Erwin E. Harbat
Kristine A. & Steven P. Harris
Kathleen Heilig &
Kurt A. Schwinghammer
Kathryn Heaney &
Kurt A. Schwinghammer
Kathyann Heilig
Athole G. Jacobi
Barbara M. Jordan
Ruth Kaminer
Lisa Kimbro & Ray Lynch
Colette & Shawn P. Kleitz
Mary K. Kulp
Alexis Kurtzman
Jessica & Alexander Kutikov
Stephen La Neve
Kathleen M. Lardani
Arnold Levin
Irwin S. Love
Wendy H. & Solomon C. Luo
Virginia R. Martin
Lynn Martin Haskin &
Donald L. Haskin
James McDermott
Catherine McDevitt
Daniel McGraw
Carol A. Meadows
Susan K. Minarik
Irina Mitrea
John P. Moran
Gordon Morewood
Kathleen & Francis X. Morris
Bridge & Michael D. Mulcahy
William J. Munizza
Patricia S. & Robert S. Nase
Brendan O’Connell
C. Tracy & Jeffrey H. Orleans
Irma E. Peoples
Anna Marie & William Petersen
Margo B. & Daniel Polett
Kevin Putman
Kim L. Rainey-Nichols &
Scott J. Nichols
Christopher Reed
Cynthia Reiss-Clark
Lori & Nicholas Renzi
Louella Richardson
Jill S. & Norma G. Rosenblum
Jesse Ruth
Barry S. Silver
Donna L. Skerrett
Cynthia & Howard S. Solganick
Kristin & Kevin Sterling
Peggy & Brian Strecker
The Estate of Henry Stuebner
Elaine W. Sykes
Marsha & Barry Taitelman
Joseph A. Tracy
Laura & Walter Whetstone
Robin A. & David L. Wiez
Robert L. Winfree
Shelley Wolf Harris &
Steven P. Harris
Barbara M. & Robert C. Young
Yan Wang & Michael Yu

Partners' Circle
$1,000 - $2,499
Lisa Adamitis
Patricia Adams
Karen Albright
Karen M. Allen
Anonymous
Gerald F. Arieth
Scott Ashline
Suzanne B. Balbirer
Beth Ballentine
Janet H. & Ralph V. Barndt
Dennis C. Barnes
Mildred A. Barr
Eugene H. Bayard
George M. Beschken
Virginia T. & Nixon L. Beyer
C. Robert Bivenour
Nellie C. Blackwell
Linda C. & James Bluebello
Theodore T. Bobroski
Theresa & Richard M. Bobroski
Mary Anne Bogie
Allison & Barry Boise
Heather Bonura
Stephen Booth
Judith L. Bowen
Elizabeth & Hugh Bowerman
The Estate of Randall R. Boyer
Laura & Kerry Brandt
Elizabeth E. Brennan
Mary Jane &
James H. Brenneman
Sarah Brett
James Brower
Lloyd & W. Thachker Brown
Rhea & James Brown
The Estate of Mary J. Brunini
Ilene & Edward A. Bulanowski
Patricia A.* & Robert C. Busby
Kathleen A. Butzloff
Devon E. & Todd A. Byers
Linda M. & Charles W. Callahan
Donna Lee & Harry E. Cann
Diane & Warren B. Chaien
Judith Chasin & Eric M. Horwitz
Chiachi Chen
Kathy & David Y. Chen
Lori & Michael Chewkanes
In Su Chon
Julie Christie
Marlene & Dominick A. Cipollini
Elizabeth R. & Richard Cohen
Jane & Robert Cohen
Joan R. & Frederick M. Cohen
Ruth L. & Stanley H. Cohen
Richard D. Colucci
Karen A. & Jay B. Comly
Denise C. Connolly &
Ronald L. Wolf
Doris M. & Nelson B. Cooney
Fredi & Harry S. Cooper
Geoffrey B. Cox
Joan F. & Henry Dantzig
Robert L. D’Avanzo
Janet C. & Aron Davidson
Katherine I. & Dennis N. Davis
Joy A. & John De Luca
Paula & Jason Dela Penna
Crystal S. Denlinger
Krista R. & John G. Devlin
Susanne L. & Joseph DiBianca
Kathleen & James C. Dinan
Martin J. Dolan
Gary Domeracki
Padma & Mohan Dosss
Tobe I. Dresner
Essel D. Dulaimi Al-Saleem &
Furat Al-Saleem
Roland L. Dunbrack
Rita E. & Charles E. Dunleavy Jr.
William B. Dwyer
Sherri & Martin Edelman
Joanna Ehlers
Hormoz Ehyae
Carol Elfant
Dawn L. Elliott & Chris Balestrini
Diane Entrikin
Maria Escrtil
John Evans
Joan M. Fagan
Daria & Jeffrey M. Farma
Ann & James D. Faust
Annette & Lee Favorite
Robert E. Fenster
Carol W. & Anthony E. Fiorito
Patrick Fisher
Betteanne Fitzwater
The Estate of Anna L. Flack
Judith H. & Stephen D. Flanagan
Amber L. & David C. Flynn
Richard T. Forchion
Lorine S. & Benjamin Forman
Jeffrey H. Forster
Mark B. Fox
Margaretha J. & Charles A. Fritz
Sharon & Alan W. Fritz
Scott Futrell
Mary L. & Frederick Gallagher
Tamarah & Patrick Galligan
Patricia & Mark D. Gerner
Catherine R. Getchell
Eileen B. Gibbons
David R. Gill
James Gillespie Jr.
Phylis S. Gitlin
Hilary & Michael D. Glenn
William R. Goldman
Eileen F. & William A. Goldress
Donna T. & Lewis F. Gould
Marlou & David Greed
Susan J. & Robert Gretz
Nancy L. Grove & Jim Bunderla
Rose Marie & William D. Gruccio
Jeanne K. Hafer
Donors

Kyle Haley
Michael J. Hall
Barbara Halpern-Cohen & Paul Cohen
Cecily J. Harmon
Crissy & Joel Helmke
Alice C. Hennessy
Marie T. & Adam Hepp
Carla & Enrique Hernandez
Evelyn & Michael Hernandez
Joyce B. & Harvey D. Hertzler
John E. Hessenthaler
The Estate of Eleanor J. Hillegas
Ellen Hollin
David M. Hoopes
Irmtraud R. Hotz
Kenneth A. Hullings
Linda & James L. Hunsicker
James E. Hyer
Barbara T. & Kevin Iisen
Anne E. & John Jadwin
Susan E. Johnson & James J. Flynn
Loretta & Samuel J. Jones
Mary M. Jones
Joanne Joyce
John Kaczmar
Carolyn G. & Michael W. Keefe
Bernard J. Keigher
Gloria & Martin V. Keiper
James P. Kilkenny
Michael Kincaid
Walter C. Kinzinger
Ellen & Frank R. Koons
Shari & Frank Koretsky
Kristin & Brian R. Kozera
Elizabeth A. & William Krisovitch
Thomas G. Kupp
Jeannine & James Lajeunesse
Anna Maria Larenz
Mary Ellen & Kenneth W. Lee
Laura & Daniel S. Levin
Sarah Jane Levine
Miriam F. & Michael Lieberman
Linda R. & Theodore Lieberman
LaTonya & Arden L. Liverman
Natalie & Bruce Lotier
James E. Mackin
Amy B. MacLean
Gregory Magee
Brande Malcette & Frank Falzett
Tina Martocello-Gricoski & John J. Gricoski
Caitlin Mason
James W. Masterson
Jenna May
Thomas F. McCrean
Joseph McFadden
Thomas Mcgowan
Sandy & William J. McMahon
Christopher W. McNichol
Dorothy & John E. Meggitt
Liz & Jonathan Meister
The Estate of Joel H. Merow
Susan & HalMichels
Barton N. Milestone
Arlene L. Miller*
Eric R. Miller
James W. Miller
Keiko & George L. Miller
Judith & James F. Mitchell III
Bonard Moise
David Moran
Michael J. Morris
William I. Mower
Ruth M. & Preston L. Moyer
Diane & Martin Mozzo
Claire & Thomas J. Mulvany
Christine Muscarnero & Sameer A. Patel
Philip Muscarnero
John G. Nalesnik
O. George Negrea
Matthew Nessel
Carl Nord
Amy & Patrick J. O'Brien
Barbara O'Donnell
Katherine A. Odowr-Portnoy & Alan Portnoy
Alan R. Offermann
Ephe A. Oliver
Deena J. & Brian O'Neill
Roseann & Robert Odpnye
Lisa Oswald
Heidi & Scot D. Pannepacker
Nicholas Panos
Rosaleen B. & Richard Parsons
Aris Pasles
Manish M. Patel
Pradeep R. Patel
Mary B. Patterson
Richard E. Patton
Doris L. Peck
Patricia A. & Thomas W. Peddie
Jane G. Pepper
Beatrice C. Pick
Denise H. & Jeffrey H. Portner
Margaret E. & Anthony C. Pratt
Estelle & Stuart E. Price
Valerie & Robert A. Price
The Estate of
Theresa Reed Clayton
Glen Reed
Tony Reed
Mary A. Reilly
Ellen & Peter L. Reiss
Philip A. Rickey
Adela Riggione
Janice & Charles Riley
Andrew B. Roberts
Nancy & Brian D. Robinson
Richard C. Roden
Heinrich Roder
Anna Rodriguez
Lucyann M. & John J. Roley Sr.
Elizabeth A. & Gerald B. Rorer
Ruth K. Rosebaum
Shari & Mark Rosenberg
Deborah K. & David E. Ross
Katie & Robert Russell
William J. Ryan
Karen M. Sadlowski
Zina & Firas A. Saidi
Donald Saxton
Tina Schecter
Alana R. Schwedel
Thomas Seaman
Josephine C. Sha
Gregory T. Shaw
Elizabeth M. Shea
Kathryn Shively McKissok & J. Bruce McKissok
Elin S. Sigurdson & John A. Ridge
Anna Marie & Rudolph Skalka
Renee Skeels
Sandra L. Snyder
Denise P. Sottilare
Rachel L. Springer
Michael Stander
Zelda R. Stern
Janice A. Stilley
Shirley E. & John E. Stoddard III
Steven J. Storh
Sud Subrahmanyah
Craig Sullivan
Pauline & Michael J. Sweeney
George Taylor
Priscilla & Joseph R. Testa
Jacqueline G. & Frederick P. Thomas
Dorothy M. & Edward Tost Jr.
Louise & Thomas R. Tritton
Winifred L. & Norman Troxel
Catherine Tuite & Eric Rosenberg
Betsy P. Ulmer
Julie M. Van Campen
David R. Van Zant
Marilyn F. & Daniel F. Veber
Elizabeth & John H. Velardi
Carl D. Vranaka
Rosalia Viterbo & Michael G. Pepe
Cynthia C. & Daniel J. Walsh
Maryanne Walsh
Elizabeth R. & David S. Wampler
Joseph J. Ward
Herbert Wartenberg
Elizabeth & Robert Watts
Miriam & Homer Weaver
Stephanie Weiss & Hugh McLaughlin
Beatrice & Richard Wernick
Elizabeth & Johnathan Whetstone
Monica L. Wrenn
M. Curtis Young
Susan S. Zuccotti
Ervin Zucker

CORPORATIONS, FOUNDATIONS & ORGANIZATIONS

Leaders’ Circle
$20,000+
Alternatives Research & Development Foundation
American Cancer Society
American Lung Association
Conquer Cancer
The ASCO Foundation
Basser Center for BRCA
Bladder Cancer Advocacy Network
Board of Associates of
Fox Chase Cancer Center
• Bucks County Chapter
• Montgomery County Chapter
• Friends of Fox Chase Cancer Center
• Jimbo’s Squad
• Young Professionals Chapter
Christopher M. Fuga
Memorial Fund
ECOG-ACRIN Cancer Research Group
Eli Lilly and Company
Elliot-Lewis Corporation
GIST Cancer Research Fund
Hearst Foundations
Edwin M. Lavino Foundation
Leukemia Research Foundation
Lutron Foundation
Lymphoma Research Foundation
The Lynx Group
MANKKA Institute
The G. Harold & Leila Y. Mathers Foundation
National Comprehensive Cancer Network Inc.
Friends’ Circle
$5,000 - $19,999
Abington Friends School
AHEPA Cancer Research Foundation, Fifth District
Alpha Theta Alpha
BeiGene USA Inc.
Broughton Foundation
C. F. Martin & Co.
Capital City Cancer Classic NJ
Caris Life Sciences
Comcast Universal
Envigo RMS
Exelixis Inc.
Exelon Foundation
Foundation Medicine
Genentech Inc.
GlaxoSmithKline
Guardant Health
Incyte Corporation
Isabella P. Spratt Fund
Jenkintown Medical Associates
Johnson & Johnson/Janssen Oncology
The McGrorty Foundation Inc.
Merck & Company Inc.
The Morris S. & Florence H. Bender Foundation
Natera
Network for Good
Norristown Bocce League
Novartis Pharmaceuticals Corporation
OncoSec Immunotherapies
Oscar H. & E. Ida Luckner Memorial Fund
Pfizer Inc.
Ride Hard Breathe Easy
Rita R. Holman Breast Cancer Foundation Inc.
Sanofi Foundation for North America
Sarah & Toby Wolfberg Endowment Fund
Tanner Industries Inc.
Tempus Labs Inc.
The TJX Foundation Inc.
Thurston Charitable Foundation
Ukrainian American Sports Center
United Way of Greater Philadelphia and Southern New Jersey
UroGen Pharma
The V Foundation for Cancer Research
Vertical Bridge REIT LLC
The Walter Henry Freygang Foundation
Elizabeth Anderson Society
The Elizabeth Anderson Society honors thoughtful friends of Fox Chase who have established gifts in the form of a bequest, gift annuity, charitable remainder trust, charitable lead trust, life insurance policy, retirement account, or select gifts of real estate.
Anonymous
Suzanne Balbirer
Toni-Lee Beigel
Catherine & Walter G. Bittner
Kathleen P. & George R. Blinn
Kay & Mike Breuninger
Christine & Harry Bridges
Kathleen Bullano
Patricia A.* & Robert C. Busby
Margaret A. Coughlin
Maureen E. Cullen
Elizabeth & John Dambrowski
Helen R. Davis
Nancy S. Day
Carol A. & Louis E. Della Penna Sr.
Linda & Robert Devlin
Ira R. Dolich
Kendra B. Eager
Carol Elfant
Barbara R. & Alfonse J. Gabriele
Helen J. Gebhardt
Catherine R. Getchell
Jane E. Hollenbach
Alice M. Hungerford
David P. Ineich
Nancy & Rodney D. Johnson
Joan E. Jones
Mary Ann Jones
Barbara R. & Charles Kahn Jr.
Edwin S. Kalman
Janet C. Kistner
Beth K. Kocher-Ferraro & Frank Ferraro
Richard Koenig
Janet B. Kovacs
Geraldine M. Kozempel
Michael Levin
Naomi P. & Philip E. Lippincott
Susan & William G. Little
Angela M. Lynch
Nancy & M. Michael Markowich
Matthew Mellett
Richard B. Millham Sr.
Evalind Minor
Beatrice Mintz
Judith A. & James F. Mitchell III
Diane & David M. Morgan
Michael J. Nauss
Elma Neeld
Diane W. Nyland
John E. Orban III
Sandra L. Paugh
Wenona & Raymond A. Paul Jr.
Jane G. Pepper
Beatrice C. Pilch
Clare K. Porac
Joanne & Alexander Rankin
Ann L. & Frank E. Reed
Joseph P. Rees
Richard C. Roden
Dominic Romagano
Jayne H. & Paul I. Rosen
John Ruggio
Daphne B. Sawyer
Cecily J. Sawyer-Harmon
Carol Schramek
Karen Schwartz
Josephine Scully
Barbara L. Sparks
Zuzanna L. & Roger J. Stankay
Nancy K. Switzer
Norma Tither
Wendy B. Trow-Fox & Remly L. Fox
Adelle E. Veihl
Sandra W. & Timothy C. Weckesser
Justin L. Young
Joyce C. Zimmerman
*Deceased
### Financials

#### Philanthropy Snapshot

- **$16,800,060**
  - Total Philanthropic Support
- **$700,000**
  - Raised at In Vino Vita
- **$400,000**
  - In Vino Vita Money That Will Go to Pilot Research Funding
- **11,073**
  - Total Donors
- **4,054**
  - Total New Donors
- **764**
  - Current Donors Who Have Given 30+ years
- **$367,408**
  - Board of Associates Total Gifts

Numbers represent Fiscal Year 2021

#### Volunteer Snapshot

- **526**
  - Scientific Publications
- **140,503**
  - Outpatient Visits
- **8,631**
  - New Patients
- **14**
  - New Faculty Members
- **277**
  - Volunteers
- **67,034**
  - Total Volunteer Hours
- **$235,432**
  - Volunteer Department Budget
- **$1,913,150**
  - Value of Hours
- **$1,677,718**
  - Net Value Added to Fox Chase

*Based upon the independent sector value of $28.54/hr.

#### Types of Cancers Treated

- **Prostate: 21%**
- **Breast: 17%**
- **Other: 13%**
- **Lung: 10%**
- **Gynecological: 8%**
- **Skin: 8%**
- **Kidney: 7%**
- **Colorectal: 5%**
- **Bladder: 5%**
- **Head & Neck: 4%**
- **Pancreas: 2%**

#### 2021 By the Numbers

- **526**
  - Scientific Publications
- **140,503**
  - Outpatient Visits
- **8,631**
  - New Patients
- **14**
  - New Faculty Members

#### Investigator Initiated Clinical Research Studies

- **91**

Currently Enrolling Clinical Research Studies

#### Actively Enrolling Clinical Research Studies

- **294**
### Clinical Snapshot (In Thousands) FY21

**TEMPLE UNIVERSITY HEALTH SYSTEM CANCER SERVICE LINE REVENUES — CLINICAL ACTIVITY***

<table>
<thead>
<tr>
<th>Revenue Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Care Revenue — Hospital</td>
<td>$506,960</td>
</tr>
<tr>
<td>Patient Care Revenue — Physicians</td>
<td>$33,939</td>
</tr>
<tr>
<td>Philanthropy, Outreach &amp; Other</td>
<td>$15,676</td>
</tr>
<tr>
<td><strong>Clinical Revenue</strong></td>
<td><strong>$556,575</strong></td>
</tr>
</tbody>
</table>

**TEMPLE UNIVERSITY HEALTH SYSTEM CANCER SERVICE LINE OPERATING EXPENSES - CLINICAL ACTIVITY***

<table>
<thead>
<tr>
<th>Expense Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salaries &amp; Benefits</td>
<td>$212,492</td>
</tr>
<tr>
<td>Supplies &amp; Pharmaceuticals</td>
<td>$185,479</td>
</tr>
<tr>
<td>Purchased Services</td>
<td>$66,922</td>
</tr>
<tr>
<td>Other Expenses</td>
<td>$13,939</td>
</tr>
<tr>
<td><strong>Clinical Expenses</strong></td>
<td><strong>$478,832</strong></td>
</tr>
</tbody>
</table>

**KEY PATIENT CARE STATISTICS**

<table>
<thead>
<tr>
<th>Statistic</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Patients</td>
<td>8,631</td>
</tr>
<tr>
<td>Hospital Admissions</td>
<td>3,484</td>
</tr>
<tr>
<td>Surgical Procedures</td>
<td>4,940</td>
</tr>
<tr>
<td>Chemotherapy Infusions &amp; Related Procedures*</td>
<td>39,643</td>
</tr>
<tr>
<td>Radiation Therapy Treatments*</td>
<td>33,344</td>
</tr>
</tbody>
</table>

*Numbers are for the Temple University Health System Cancer Service Line and include revenue and expenses related to oncology from both Fox Chase Cancer Center and Temple University Hospital Inc.

### Research Snapshot

**ACTIVE FUNDED PROJECTS**

<table>
<thead>
<tr>
<th>Funding Source</th>
<th>Number of Projects</th>
<th>Direct Costs</th>
<th>Total Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCI</td>
<td>115</td>
<td>$13,286,474</td>
<td>$21,836,242</td>
</tr>
<tr>
<td>Other NIH</td>
<td>80</td>
<td>$14,431,471</td>
<td>$22,760,460</td>
</tr>
<tr>
<td>Other</td>
<td>35</td>
<td>$3,859,410</td>
<td>$5,590,244</td>
</tr>
<tr>
<td><strong>Subtotal of peer-reviewed</strong></td>
<td><strong>230</strong></td>
<td><strong>$31,577,555</strong></td>
<td><strong>$50,186,946</strong></td>
</tr>
</tbody>
</table>

**NON PEER-REVIEWED**

<table>
<thead>
<tr>
<th>Funding Source</th>
<th>Number of Projects</th>
<th>Direct Costs</th>
<th>Total Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry</td>
<td>203</td>
<td>$13,040,739</td>
<td>$17,262,687</td>
</tr>
<tr>
<td>Other non peer-reviewed</td>
<td>46</td>
<td>$3,616,616</td>
<td>$4,237,047</td>
</tr>
<tr>
<td><strong>Subtotal of non peer-reviewed</strong></td>
<td><strong>249</strong></td>
<td><strong>$16,657,355</strong></td>
<td><strong>$21,499,734</strong></td>
</tr>
</tbody>
</table>

**GRAND TOTAL**

|                  | 479               | $48,234,910  | $71,686,680 |
Leadership & Faculty

Senior Administrators

Robert Uzzo, MD, MBA, FACS
Interim CEO of the Hospital at Fox Chase Cancer Center
Chair, Department of Surgery

Jonathan Chernoff, MD, PhD
Cancer Center Director
Senior Vice President

David Wiest, PhD
Scientific Director, Research Institute

Glenn F. Rail, PhD
Chief Academic Officer

Joel Helmke, MSHP, FACHE 2
Chief Operating Officer

Ray Lynch, CPA, MBA
Chief Financial Officer

James L. Helstrom, MD, MBA
Chief Medical Officer

Anna L. Rodriguez, MSN, MBA, RN, OCN, NEA-BC 2
Chief Nursing Officer
Vice President, Nursing and Patient Services

Shawn Kleitz
Chief Development Officer

Fox Chase Cancer Center Foundation
Board of Directors

Chair: Donald E. Morel Jr., PhD
Vice Chair: Louis E. Della Penna Sr.
William J. Federici
Edward A. Glickman
Julia Gopherud
Lewis F. Gould Jr.
Thomas W. Hofmann
Barbara Ilsen
Margot Wallace Keith
Geoffrey Kent
Peter Kriemler
Philip E. Lipincott
Solomon C. Luo, MD
David G. Marshall
Anna Marie Ahn Petersen
Tina Pidgeon
Kenneth Shopshire
Thomas R. Tritton, PhD

Fox Chase Cancer Center Endowed Chairs

LOUIS DELLA PENNA FAMILY
CHAIR IN HEAD & NECK ONCOLOGY
John A. “Drew” Ridge, MD, PhD, FACS
Chief, Head and Neck Surgery

CAROL & LOUIS DELLA PENNA
CHAIR IN UROLOGIC ONCOLOGY
Richard E. Greenberg, MD, FACS
Professor, Department of Surgical Oncology

G. MORRIS DORRANCE JR.
CHAIR IN MEDICAL ONCOLOGY
Martin J. Edelman, MD
Chair, Department of Hematology/Oncology

THE GLORIA & EDMUND M. DUNN
CHAIR IN THORACIC ONCOLOGY
Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology

MARVIN S. GREENBERG, MD,
CHAIR IN PANCREATIC CANCER SURGERY
John P. Hoffman, MD, FACS
Chief, Pancreaticobiliary Service

PAUL GROTZINGER & WILBUR RAAB
CHAIR IN SURGICAL ONCOLOGY
Stephen C. Rubin, MD
Professor, Division of Gynecologic Oncology

SAMUEL M.V. HAMILTON
CHAIR IN CANCER PREVENTION
Margie L. Clapper, PhD
Deputy Chief Scientific Officer

GERALD E. HANKS
CHAIR IN RADIATION ONCOLOGY
Eric M. Horwitz, MD, FABS, FASTRO
Chair, Department of Radiation Oncology

THE DONALD E. & SHIRLEY C.
MOREL, STANLEY & STELLA BAYSTER
CHAIR IN MOLECULAR DIAGNOSTICS
Mariusz A. Wasik, MD
Chair, Department of Pathology

G. WILLING “WING” PEPPER
CHAIR IN CANCER RESEARCH
Robert G. Uzzo, MD, FACS
Chair, Department of Surgical Oncology

STANLEY P. REIMANN
CHAIR IN ONCOLOGY RESEARCH
Jonathan Chernoff, MD, PhD
Chief Scientific Officer

AUDREY WEG SCHAUS & GEOFFREY ALAN WEG
CHAIR IN MEDICAL SCIENCE
David S. Weinberg, MD, MSc
Chair, Department of Medicine

ROBERTA R. SCHELLER
CHAIR IN UROLOGIC ONCOLOGY
Alexander Kutikov, MD, FACS
Chief, Division of Urology and Urologic Oncology

JACK SCHULTZ
CHAIR IN BASIC SCIENCE
Johnathan R. Whetstine, PhD
Director, Cancer Epigenetics Institute

WILLIAM WIKOFF SMITH
CHAIR IN CANCER RESEARCH
Erica Golemis, PhD
Deputy Chief Scientific Officer

TIMOTHY R. TALBOT JR.
CHAIR IN CANCER RESEARCH
Mary B. Daly, MD, PhD, FACP
Chair Emerita, Department of Clinical Genetics

CAROL & KENNETH WEG
CHAIR IN HUMAN GENETICS
Joseph R. Testa, PhD, FACMG
Co-Leader, Cancer Biology Program

H.O. WEST & J.R. WIKE
CHAIR IN CANCER RESEARCH
J. Robert Beck, MD
Professor Emeritus

ROBERT C. YOUNG, MD,
CHAIR IN CANCER RESEARCH

44  Fox Chase Cancer Center • Prevail • Annual Report 2021
Clinical Faculty

Department of Bone Marrow
Transplant and Cellular Therapies
Chair: Henry Fung, MD
Peter Abdelmessieh, DO, MSc
Rashmi Kanaf, MD
Michael Jay Styler, MD
Asya Varshavsky-Yanovsky, MD, PhD

Department of Clinical Genetics
Chair: Michael J. Hall, MD, MS
Mary B. Daly, MD, PhD
Elias Obeid, MD, MPH
Emmanuel Quinn, MD
Iberia Romina Sosa, MD, PhD
Joseph Treat, MD
Namrata Vijayvergia, MD

Supportive Oncology & Palliative Care
Marcin Chwistek, MD
Molly Collins, MD
Dylan Sherry, MD

Fox Chase Cancer Center at Temple University Hospital

Jahi Mittal, MD
Anura Padmanabhan, MD
Alvaro Pereira-Rico, MD
Deric Savior, MD

Department of Medicine
Chair: David S. Weinberg, MD, MSc
Cardiology
Daniel Edmundowicz, MD, MS
Dermatology
Abhishek Aphale, MD
Gabriel Isaza, MD
Anthony Santoro, MD
Endocrinology
Christian Koch, MD, PhD
Pankaj Sharda, MD
Gastroenterology
Jennifer Higa, MD
Minhuyen Nguyen, MD
Jeffrey Tokar, MD
Hospitalists
Usman Ali, MD
Elizabeth A. Bourne, MD
Robert Brenchak, MD
Daniel Hollier, MD

Kristen Manley, MD
Kenneth Patrick, MD
Rajkumar Sarkar, MD
Krishnalatha Sreekrishnanayilam
Devakiamma, MD
Devendra Tripathi, MD
Physical Medicine & Rehabilitation
Gilbert Lafontant, MD
Psychiatry
Emmie Chen, MD
Suzanne Dubravka, MD
Paula Finestone, PhD
Pulmonary Medicine
Sheela Ahmed, MD
Alan Haber, MD
Rohit Kumar, MD
Christopher Manley, MD

Department of Pathology
Chair: Mariusz Wasik, MD
Donald Baldwin, PhD
Tahseen I. Al-Saleem, MD
Harry S. Cooper, MD
Hormoz Ehy, MD
Douglas Flieder, MD
Yulan Gong, MD
Min Huang, MD
Nicholas Mackrides, MD
Rajeswari Nagarathinam, MD
Reza Nejati, MD
Arthur S. Patchefsky, MD
Jianming Pei, MD
Jianming Pei, MD

Department of Radiation Oncology
Chair: Eric M. Horwitz, MD
Penni Anderson, MD
Jo Ann Chalal, MD
Randi Cohen, MD, MS
Thomas Galloway, MD
Mark Hallman, MD
Sheppy Hayes, MD
Krisha Howell, MD
Sameera Kumar, MD
Douglas Lee, DO
Joshua Meyer, MD
Mark Sobczak, MD
Sangeeta Tyerech, MD
Stephanie Weiss, MD
Jessica Karen Wong, MD

Department of Surgical Oncology
Chair: Robert G. Uzzo, MD, MBA
Allison Aggon, DO
Cynthia Bergman, MD
Richard Bleicher, MD
Jason Castellanos, MD
David Chen, MD
Christina Chu, MD
Andres Correa, MD
Paul Curcillo, MD
John Michael Daly, MD
Jeffrey Farma, MD
Stephanie Greco, MD
Richard E. Greenberg, MD
Stephanie King, MD
Alexander Kutikov, MD
Kelvin Lau, MD
Jeffrey Liu, MD
Gina Mantia-Smaladone, MD
Sameer Patel, MD
Theresa Pazzonis, MD
Andrea Porpiglia, MD
Sanjay Reddy, MD
John A. “Drew” Ridge, MD, PhD
Stephen Rubin, MD
Cecelia Schmalbach, MD, MSc
Elin Sigurdson, MD, PhD
Marc Smaladone, MD
Stacey Su, MD
Neal Topham, MD
Rosalia Viterbo, MD
Anesthesiology
Eric Deveaux, MD
Amanda Hargrove, MD
James L. Helstrom, MD
Kristin K.G. Krauss, MD
Michelle McMaster, MD
Gunpreet Mundi, MD
Maria Munoz-Allen, MD
Dmitry Roberman, DO
F. Felipe Suero, MD
Florence Macenat Sulzynski, MD

Research Faculty

Blood Cell Development & Function
Program Leaders
Siddharth Balachandran, PhD
David L. Wiest, PhD
Primary Members
Mike Autieri, PhD
Kerry S. Campbell, PhD
Israel Cañadas, PhD
Henry Fung, MD
Kyoko Hayakawa, MD
Lisellotte Jensen, PhD
Nadia Khan, MD
Suzanne Doubrava, MD
Emmie Chen, MD
Gilbert Lafontant, MD
John Michael Daly, MD
Jeffrey Farma, MD
Stephanie Greco, MD
Richard E. Greenberg, MD
Stephanie King, MD
Alexander Kutikov, MD
Kelvin Lau, MD
Jennifer Higa, MD
Yi Li, MD, MSc
F. Felipe Suero, MD
Florence Macenat Sulzynski, MD

Annual Report 2021 • Prevail • Fox Chase Cancer Center 45